Background: Transcatheter aortic valve implantation (TAVI) has emerged as a suitable alternative to surgical valve replacement for patients with severe, symptomatic, calcified aortic stenosis and a background of co-morbidities, which can make surgery a high-risk option. It has also evolved as an alternative for degenerative prosthetic heart valve disease.
Objective: To test the efficacy, early and after 6 months' outcome of transcatheter aortic valve implantation in patients with severe aortic stenosis and at high operative risk for surgical valve replacement.
Methods: 36 Patients with severe symptomatic aortic stenosis and high risk for conventional surgical aortic valve replacement admitted to National Heart Institute during the period from February 2013 till February 2019 were included in the study.
Results: Out of 36, None to trace prosthetic aortic regurgitation was found and no patients had severe prosthetic aortic regurgitation. After six months, 4 patients died. 4 patients (11.1%) developed CHB need PPM and 5 patients (13.9%) developed new LBBB
Conclusion: TAVI is a safe and effective procedure and can be considered as a viable alternative to conventional open-heart surgery in selected high-risk patients with severe symptomatic aortic stenosis